Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
In the open-label, Canadian Phase IIa TPI ASM8-206 trial in 12 patients, inhaled 8 mg ASM8 once daily for 4 days met the primary endpoint of significantly reducing sputum eosinophil count at 7 and 24 ...